Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 369 clinical trials
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

growth factor
graft versus host disease
nitrosourea
brainstem tumor
myelosuppressive chemotherapy
  • 990 views
  • 12 Jun, 2021
  • 114 locations
A Study of PDR001 in Combination With LCL161 Everolimus or Panobinostat

The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

  • 370 views
  • 13 May, 2021
  • 33 locations
Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their …

cancer
squamous cell carcinoma
atezolizumab
lung cancer
pd-l1
  • 89 views
  • 03 Feb, 2021
  • 11 locations
A Phase II Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID (twice daily) and 1600 mg QD (once daily). Subjects will be screened for eligibility within 21 days of the planned date of the first dose of tazemetostat and enrolled into one of 8 cohorts: …

small molecule
growth factor
malignant peripheral nerve sheath tumor
synovial sarcoma
kidney function tests
  • 0 views
  • 31 May, 2021
  • 25 locations
ESTxENDS Trial: MN Substudy - Micronuclei in Buccal Epithelium a Surrogate Measure of Future Cancer Risk Induced by Electronic Nicotine Delivery Systems (ENDS/Vaporizer/E-cig)

-related outcomes, in particular incident of mouth-, lung- and kidney- cancers.

cigarette smoke
tobacco smoke
nicotine replacement
cancer
  • 2 views
  • 25 Jan, 2021
  • 8 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors Lymphomas or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

alopecia
HIV Infection
prednisone
sunitinib
heart failure
  • 6087 views
  • 09 Jun, 2021
  • 1016 locations
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3). The drug may treat cancer by interfering with the effect of the NTRK genes on cancer growth. The study …

kidney function test
solid tumor
NTRK
brain metastases
experimental drug
  • 1310 views
  • 28 May, 2021
  • 79 locations
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can …

breast cancer
NTRK
tyrosine
measurable disease
lung cancer
  • 0 views
  • 03 Jun, 2021
  • 195 locations
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR.

oxaliplatin
pd-l1
mek inhibitor
carcinoma
measurable disease
  • 230 views
  • 08 May, 2021
  • 28 locations
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors

small lung
lung cancer
durvalumab
medi4736
lung carcinoma
  • 50 views
  • 06 Jun, 2021
  • 8 locations